Novartis backs eye drop maker in $20M round, meds to fill gap left by Eylea/Lucentis
Eye-obsessed Novartis, in a syndicate with other investors, has backed a $20 million round for Swiss biotech Oculis. The hope is to see the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
